7 Humoral response to hepatitis C virus

Biomedical Research Reports

Volumn 2, Issue C, 2000, Pages 125-145

  Weiner, Amy J ^a   Chien, David ^a   Choo, Qui Lim ^a   Coates, Stephen R ^a   Kuo, George ^a   Houghton, Michael ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1242334096     PISSN: 18745326     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-5326(00)80011-3     Document Type: Article

References (149)

1. Alter H.J. To C or Not to C: these are the questions. Blood 85 (1995) 1681-1695
2. Alter H.J. Hepatitis C in asymptomatic blood donors. Hepatology 26 (1997) 29S-33S
3. Alter M.J. Epidemiology of hepatitis C. Hepatology 26 (1997) 62S-65S
4. Hoofnagle J.H. Hepatitis C: the clinical spectrum of disease. Hepatology 26 (1997) 15S-20S
5. Seeff L.B. Natural history of hepatitis C. Hepatology 26 (1997) 21S-28S
6. Hu K.-Q., and Tong M.J. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29 (1999) 1311-1316
7. Choo Q.-L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989) 359-362
8. Prince A.M. Non-A, non-B hepatitis viruses. Annu Rev Microbiol 37 (1983) 217-232
9. Shih W.-K., Esteban J.I., and Alter H.J. Non-A, Non-B hepatitis: Advances and unfulfilled expectations of the first decade. Liver Dis 8 (1986) 433-452
10. Choo Q.-L., Berger K., Kuo G., and Houghton M. Detection and mapping of immunologic epitopes expressed by bacterial cDNA clones of the hepatitis C virus. In: Hollinger F.B., Lemon S.M., and Margolis H.S. (Eds). Viral hepatitis and liver disease (1991), Williams & Wilkins, Baltimore, MD 345-346
11. Kuo G., Choo Q.-L., Alter H.J., et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244 (1989) 362-364
12. Chien D.Y., Choo Q.-L., Tabrizi A., et al. Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease. Proc Natl Acad Sci U S A 89 (1992) 10011-10015
13. Choo Q.-L., Richman K.H., Han J.H., et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 88 (1991) 2451-2455
14. Houghton M. Hepatitis C viruses. In: Fields B.N., Knipe D.M., Howley P.M., et al. (Eds). Fields virology (1996), Lippincott-Raven, Philadelphia 1035-1057
15. Major M.E., and Feinstone S.M. The molecular virology of hepatitis C. Hepatology 25 (1997) 1527-1538
16. Lok A., Chien D., Choo Q.-L., et al. Antibody response to core, envelop and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 18 (1993) 497-502
17. Gretch D.R. Diagnostic tests for hepatitis C. Hepatology 26 (1997) 43S-47S
18. Lok A., and Gunaratnam N.T. Diagnosis of hepatitis C. Hepatology 26 (1997) 48S-56S
19. Bassett S.E., Brasky K.M., and Lanford R.E. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol 72 (1998) 2589-2599
20. Choo Q.-L., Kuo G., Ralston R., et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 91 (1994) 1294-1298
21. Houghton M., Choo Q.-L., Kuo G., et al. Prospects for prophylactic and therapeutic hepatitis C virus vaccines. Princess Takamatsu Symp. 25 (1995) 237-243
22. Feinstone S.M., Alter H.J., Dienes H.P., et al. Non-A, non-B hepatitis in chimpanzees and marmosets. J. Inf. Dis. 144 (1981) 588-598
23. Farci P., London W.T., Wong D.C., et al. The natural history of infection with hepatitis C virus (HCV) in chimpanzees: comparison of serologic responses measured with first- and second-generation assays and relationship to HCV viremia. J Infect Dis 165 (1992) 1006-1111
24. Vallari D.S., Jett B.W., Alter H.J., Mimms L.T., Holzman R., and Shih J.W. Serological markers of post-transfusion hepatitis C viral infection. J Clin Microbiol 30 (1992) 552-556
25. Kobayashi M., Tanaka E., Matsumoto A., Ichijo T., and Kiyosawa K. Antibody response to E2/NS1 hepatitis C virus protein in patients with acute hepatitis C. J Gastroenterol Hepatol 12 (1997) 73-76
26. Chen M., Sallberg M., Sonnerborg A., et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology 116 (1999) 135-143
27. Beld M., Penning M., Van Putten M., et al. Quantitative antibody responses to the structural (core) and nonstructural (NS3, NS4, NS5) hepatitis C virus proteins among seroconverting injecting drug users: Impact of epitope variation and relationship to detection of HCV RNA. Hepatology 29 (1999) 1288-1298
28. Lanotte P., Dubois F., Le Pogam S., et al. The kinecis of antibodies against hepatitis C virus may predict viral clearance in exposed hemophiliacs. J Infect Dis 178 (1998) 556-669
29. Clemens J.M., Taskar S., Chau K., et al. IgM antibody response in acute hepatitis C viral infection. Blood 79 (1992) 169-172
30. Quiroga J.A., van Binsbergen J., Wang C.Y., et al. Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with viral replication, histological activity, and liver disease outcome. Hepatology 22 (1995) 1635-1640
31. Brunetto M.R., Oliveri F., Rocca G., et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 10 (1989) 198-202
32. Quinti I., Hassan N.F., El Salman D., Shalaby H., El Zimatty D., Monier M.K., and Arthur R.R. Hepatitis C virus-specific B cell activation: IgG and IgM detection in acute and chronic hepatitis C. J Hepatology 23 (1995) 640-647
33. Beach M.J., Meeks E.L., Mimms L.T., et al. Temporal relationships of hepatitis C virus RNA and antibody responses following experimental infection of chimpanzees. J Med Virol 36 (1992) 226-237
34. Hilfenhaus J., Krupka U., Nowak T., Cummins L.B., Fuchs K., and Roggendorf M. Follow-up of hepatitis C virus infection in chimpanzees: determination of viraemia and specific humoral immune response. J Gen Virol 73 (1992) 1015-1019
35. Wang Y.-F., Brotman B., Andrus L., and Prince A.M. Immune response to epitopes of hepatitis C virus (HCV) structural proteins in HCV-infected humans and chimpanzees. J Infect Dis 173 (1996) 808-821
36. Chien D.Y., Choo Q.-L., Ralston R., and Spaete R. Persistence of HCV despite antibodies to both putative envelope glycoproteins. Lancet 342 (1993) 933
37. Harada S., Suzuki R., Ando A., et al. Establishment of a cell line constitutively expressing E2 glycoprotein of hepatitis C virus and humoral response of hepatitis C patients to the expressed protein. J Gen Virol 76 (1995) 1223-1231
38. Lesniewski R.R., Watanabe S., and Devare S.G. Expression of HCV envelope proteins and the serological utility of the anti-E2 immune response. Princess Takamatsu Symp. 25 (1995) 129-137
39. Fournillier-Jacob A., Lunel F., Cahour A., et al. Antibody responses to hepatitis C envelope proteins in patients with acute or chronic hepatitis C. J Med Virol 50 (1996) 159-167
40. Lee K.J., Suh Y.-A., Cho Y.G., et al. Hepatitis C virus E2 protein purified from mammalian cells is frequently recognized by E2-specific antibodies in patient sera. J Biol Chem 272 (1997) 30040-30046
41. Cerino A., Bissolati M., Cividini A., et al. Antibody responses to the hepatitis C virus E2 protein: Relationship to viraemia and prevalence in anti-HCV seronegative subjects. J Med Virol 51 (1997) 1-5
42. Psichogiou M., Katsoulidou A., Vaindirli E., Francis B., Lee S.R., and Hatzakis A. Immunologic events during the incubation period of hepatitis C virus infection: the role of antibodies to E2 glycoprotein. Transfusion 37 (1997) 858-862
43. Bassett S.E., Thomas D.L., Brasky K.M., and Lanford R.E. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol 73 (1999) 1118-1126
44. van Doorn L.-J., van Hoek K., de Martinoff G., et al. Serological and molecular analysis of hepatitis C virus envelope regions 1 and 2 during acute and chronic infections in chimpanzees. J Med Virol 52 (1997) 441-450
45. Lesniewski R., Okasinski G., Carrick R., et al. Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. J Med Virol 45 (1995) 415-422
46. Yuki N., Hayashi N., Kasahara A., et al. Quantitative analysis of antibody to hepatitis C virus envelope 2 glycoprotein in patients with chronic hepatitis C virus infection. Hepatology 23 (1996) 947-952
47. Walker C.M. Comparative features of hepatitis C virus infection in humans and chimpanzees. Springer Semin Immunopathol 19 (1997) 85-98
48. Alter H.J., Purcell R.H., Holland P.V., and Popper H. Transmissible agent in non-A, non-B hepatitis. Lancet 1 (1978) 459-463
49. Prince A.M., Brotman B., van den Ende M.C., Richardson L., and Kellner A. Non-A, non-B hepatitis: Identification of virus-specific antigen and antibody: a preliminary report. In: Vyas G.N., Cohen S.N., and Schmid R. (Eds). Viral hepatitis (1978), Franklin Institute Press, Philadelphia 633-640
50. Bradley D.W., Cook E.H., Maynard J.E., et al. Experimental infection of chimpanzees with antihemophilic (factor VIII) materials: recovery of virus-like particles associated with non-A, non-B hepatitis. J Med Virol 3 (1979) 253-269
51. Bradley D.W. Transmission, etiology, and pathogenesis of viral hepatitis non-A, non-B in nonhuman primates. In: Chisari F.V. (Ed). Advances in hepatitis research (1984), Masson, New York 268-280
52. Tabor E., Gerety R.J., Drucker J.A., et al. Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1 (1979) 463-466
53. Feinstone S.M., Alter H.J., Dienes H.P., et al. Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis 144 (1981) 588-598
54. Ching W.M., Wychowski C., Beach M.J., et al. Interaction of immune sera with synthetic peptides corresponding to the structural protein region of hepatitis C virus. Proc Natl Acad Sci U S A 89 (1992) 3190-3194
55. Weiner A.J., Geysen H.M., Christopherson C., et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 89 (1992) 3468-3472
56. Lesniewski R.R., Boardway K.M., Casey J.M., et al. Hypervariable 5′-terminus of hepatitis C virus E2/NS1 encodes antigenically distinct variants. J Med Virol 40 (1993) 150-156
57. Taniguchi S., Okamoto H., Sakamoto M., et al. A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus (E2/NS1) protein: implication for an escape from antibody. Virology 195 (1993) 297
58. Kojima M., Osuga T., Tsuda F., Tanaka T., and Okamotos H. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees. Virology 204 (1994) 665-672
59. da Silva Cardoso M., Siemoneit K., Nemecek V., Epple S., Koerner K., and Kubanek B. The serology of hepatitis C virus (HCV) infection: antibody crossreaction in the hypervariable region 1. Arch Virol 140 (1995) 1705-1713
60. Kato N., Sekiya H., Ootsuyama Y., et al. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 67 (1993) 3923
61. Kato N., Ootsuyama Y., Sekiya H., et al. Genetic drift in the hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J Virol 68 (1994) 4776-4784
62. Kato N., Ootsuyama Y., Sekiya H., et al. Humoral response to linear B cell epitopes in the terminus of the hepatitis C virus envelope glycoprotein gp72 (E2): role in protective immunity still unknown. Hepatology 22 (1995) 369-371
63. van Doorn L.J., Capriles I., Maertens G., et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol 69 (1995) 773-778
64. Nakamoto Y., Kaneko S., Ohno H., et al. B-cell epitopes in hypervariable region 1 of hepatitis C virus obtained from patients with chronic persistent hepatitis. J Med Virol 50 (1996) 35-41
65. Zibert A., Dudziak P., Schreier E., and Roggendorf M. Characterization of antibody response to hepatitis C virus protein E2 and significance of hypervariable region 1-specific antibodies in viral neutralization. Arch Virol 142 (1997) 523-534
66. Zibert A., Kraas W., Meisel H., Jung G., and Roggendorf M. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol 71 (1997) 4123-4127
67. Zibert A., Kraas W., Ross S., et al. Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection. J Hepatol 30 (1999) 177-184
68. Hijikata M., Kato N., Ootsuyama Y., Nakagawa M., Ohkoshi S., and Shimotohno K. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 175 (1991) 220-228
69. Weiner A.J., Brauer M.J., Rosenblatt J., et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180 (1991) 842-848
70. Kato N., Ootsuyama Y., Tanaka T., et al. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res 22 (1992) 107-123
71. McAllister J., Casino C., Davidson F., et al. Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J Virol 72 (1998) 4893-4905
72. Yoshioka K., Aiyama T., Okumura A., et al. Humoral immune response to the hypervariable region of hepatitis C virus differs between genotypes 1b and 2a. J Infect Dis 175 (1996) 505-510
73. Hattori M., Yoshioka K., Aiyama T., et al. Broadly reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: relation to viral loads and response to interferon. Hepatology 27 (1998) 1703-1710
74. Scarselli E., Cerino A., Esposito G., Silini E., Mondelli M.U., and Traboni C. Occurrence of antibodies reactive with more than one varient of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients. J Virol 69 (1995) 4407-4412
75. Zibert A., Schreier E., and Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 208 (1995) 653-661
76. Esumi M., Ahmed M., Zhou Y.-H., Takahashi H., and Shikata T. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus. Virology 251 (1998) 158-164
77. Farci P., Alter H.J., Govindarajan S., et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258 (1992) 135-140
78. Prince A.M., Brotman B., Huima T., Pascual D., Jaffery M., and Inchauspe G. Immunity in hepatitis C infection. J Infect Dis 165 (1992) 438-443
79. Wyatt C.A., Andrus L., Brotman B., Huang F., Lee D.-H., and Prince A.M. Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J Virol 72 (1998) 1725-1730
80. Krawczynski K., Alter M.J., Tankersley D.L., et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 173 (1996) 822-828
81. Piazza M., Sagliocca L., Tosone G., et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. Arch Intern Med 157 (1997) 1537-1544
82. Farci P., Alter H.J., Wong D.C., et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 91 (1994) 7792-7796
83. Farci P., Shimoda A., Wong D., et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93 (1996) 15394-15399
84. Shimizu Y.K., Hijikata M., Iwamoto A., Alter H.J., Purcell R.H., and Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 68 (1994) 1494-1500
85. Shimizu Y.K., Igarashi H., Kiyohara T., et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell culture. Virology 223 (1996) 409-412
86. Rosa D., Campagnoli S., Moretto C., et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 93 (1996) 1759-1763
87. Roivainen M., Piirainen L., Tysa T., Narvanen A., and Hovi T. An immunodominant N-terminal region of VP1 protein of poliovirion that is buried in crystal structure can be exposed in solution. Virology 195 (1993) 762-765
88. Li Q., Yafal A.G., Lee Y.M., Hogle J., and Chow M. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature. J Virol 68 (1994) 3965-3970
89. Page G.S., Mosser A.G., Hogle J.M., Filman D.J., Rueckert R.R., and Chow M. Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J Virol 62 (1988) 1781-1794
90. Houghton M., Choo Q.-L., Chien D., et al. Development of an HCV vaccine. In: Rizzetto M., Purcell R.H., Gerin J.L., and Verme G. (Eds). Vital hepatitis and liver disease (1996), Edizioni Minerva Medica, Torino, Italy 656-659
91. Weiner A.J., Christopherson C., Hall J.E., et al. The hypervariable amino terminus of the hepatitis C virus E2/NS1 protein appears to be under immune selection. In: Brown F., Chanock R.M., Ginsberg H.S., and Lerner R.A. (Eds). Vaccines 92. Modern approaches to new vaccines including prevention of AIDS (1992), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 303
92. Lechner S., Rispeter K., Meisel H., et al. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Virology 243 (1998) 313-321
93. Abrignani S. Immune responses throughout hepatitis C virus (HCV) infection: HCV from the immune system point of view. Springer Semin Immunopathol 19 (1997) 47-55
94. Ishii K., Rosa D., Watanabe Y., et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28 (1998) 1117-1120
95. Habersetzer F., Fournillier A., Dubuisson J., et al. Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology 249 (1998) 32-41
96. Kaito M., Watanabe S., Tsukiyama-Kohara K., et al. Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol 75 (1994) 1755-1760
97. Shindo M., Di Bisceglie A.M., Akatsuka T., et al. The physical state of the negative strand of hepatitis C virus RNA in serum of patients with chronic hepatitis C. Proc Natl Acad Sci U S A 91 (1994) 8719-8723
98. Takahashi K., Kishimoto S., Yoshizawa H., Okamoto H., Yoshikawa A., and Mishiro S. p26 protein and 33-nm particle associated with nucleocapsid of hepatitis C virus recovered from the circulation of infected hosts. Virology 191 (1992) 431-434
99. Takahashi K., Okamoto H., Kishimoto S., et al. Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts. J Gen Virol 73 (1992) 667-672
100. Ralston R., Thudium K., Berger K., et al. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol 67 (1993) 6753-6761
101. Dubuisson J., Hsu H.H., Cheung R.C., Greenberg H.B., Russell D.G., and Rice C.M. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 68 (1994) 6147-6160
102. Chiba J., Ohba H., Matsuura Y., et al. Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus. Proc Natl Acad Sci U S A 88 (1991) 4641-4645
103. Lanford R.E., Notvall L., Chavez D., et al. Analysis of hepatitis C virus capsid, E1, and E2/NS1 proteins expressed in insect cells. Virology 197 (1993) 225-235
104. Matsuura Y., Suzuki T., Suzuki R., et al. Processing of E1 and E2 glycoproteins of hepatitis C virus expressed in mammalian and insect cells. Virology 205 (1994) 141-150
105. Baumert T.F., Ito S., Wong D.T., and Liang T.J. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 72 (1998) 3827-3836
106. Spaete R.R., Alexander D., Rugroden M.E., et al. Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. Virology 188 (1992) 819-830
107. Selby M.J., Glazer E., Masiarz F., and Houghton M. Complex processing and protein: Protein interactions in the E2:NS2 region of. Virology 204 (1994) 114-122
108. Inudoh M., Nyunoya H., Tanaka T., Hijikata M., Kato N., and Shimotohno K. Antigenicity of hepatitis C virus envelope proteins expressed in Chinese hamster ovary cells. Vaccine 14 (1996) 1590-1596
109. Hijikata M., Kato N., Ootsuyama Y., Nakagawa M., and Shimotohno K. Gene mapping of the putative structural region of the hepatitis virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A 88 (1991) 5547-5551
110. Grakoui A., Wychowski C., Lin C., Feinstone S.M., and Rice C.M. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67 (1993) 1385-1395
111. Dubuisson J., and Rice C.M. Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin. J Virol 70 (1996) 778-786
112. Deleersnyder V., Pillez A., Wychowski C., et al. Formation of native hepatitis C virus glycoprotein complexes. J Virol 71 (1997) 697-704
113. Cocquerel L., Duvet S., Meunier J.-C., et al. The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. J Virol 73 (1999) 2641-2694
114. Lee J.W., Kim K.-M., Jung S.-H., et al. Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies. J Virol 73 (1999) 11-18
115. Ahmed M., Shikata T., and Esumi M. Murine humoral immune response against recombinant structural proteins of hepatitis C virus distinct from those of patients. Microbiol Immunol 40 (1996) 169-176
116. Puntoriero G., Meola A., Lahm A., et al. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J 17 (1998) 3521-3533
117. Oldstone M. Molecular anatomy of viral persistence. J Virol 65 (1991) 6381-6386
118. Peters M., Vierling J., Gershwin M.E., Milich D., Chisari F.V., and Hoofnagle J.H. Immunology and the liver. Hepatology 13 (1991) 977-994
119. Smith G.L. Virus strategies for evasion of the host response to infection. Trends Microbiol 2 (1994) 81-88
120. de la Torre J.C., and Oldstone M.B. Anatomy of viral persistence: mechanisms of persistence and associated disease. Adv Virus Res 46 (1996) 311-343
121. Zinkernagel R.M. Immunology and immunity studied with viruses. Ciba Found Symp 204 (1997) 105-125
122. Borrow P. Mechanisms of viral clearance and persistence. J Viral Hepatitis 4 (1997) S216-S224
123. Ferrari C., Penna A., Bertoletti A., et al. Antiviral cell-mediated immune responses during hepatitis B and hepatitis C virus infections. Recent Results Cancer Res 154 (1998) 330-336
124. Chapman M.S., and Rossman M.G. Comparison of surface properties of picornaviruses: Strategies for hiding the receptor site from immune surveillance. Virology 195 (1993) 745-756
125. Fish K.N., Britt W., and Nelson J.A. A novel mechanism for persistence of human cytomegalovirus in macrophages. J Virol 70 (1996) 1855-1862
126. Domingo E., and Holland J.J. Mutation rates and rapid evolution of RNA viruses. In: Morse S.S. (Ed). Evolutionary biology of viruses (1994), Raven Press, New York 161-184
127. Steinhauer D.A., Domingo E., and Holland J.J. Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 122 (1992) 281-288
128. Ogata N., Alter H.J., Miller R.H., and Purcell R.H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A 88 (1991) 3392
129. Okamoto H., Kojima M., Okada S.-I., et al. Genetic drift of hepatitis C during an 8.2-year infection in a chimpanzee variability and stability. Virology 190 (1992) 894-899
130. Major M.E., Mihalik K., Fernandez J., et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol 73 (1999) 3317-3325
131. Kolykahalov A.A., Agapov E.V., Blight K., Mihalik K., Feinstone S.M., and Rice C.M. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277 (1997) 570-574
132. Martell M., Esteban J.L., Quer J., et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66 (1992) 3225
133. Farci P., Bukh J., and Purcell R.H. The quasispecies of hepatitis C virus and the host immune response. Springer Semin Immunopathol 19 (1997) 5-26
134. Domingo E., Martinez-Salas E., Sobrino F., et al. The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance-a review. Gene 40 (1985) 1-8
135. Eigen M. On the nature of virus quasispecies. Trends Microbiol 4 (1996) 216-218
136. Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 19 (1997) 111-129
137. Monteverde A., Ballare M., and Pileri S. Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryoglobulinemia. Springer Semin Immunopathol 19 (1997) 99-110
138. McMurray R.W. Hepatitis C-associated autoimmune disorders. Rheum Dis Clin North Am 24 (1998) 353-374
139. Ray S.C., Wang Y.-M., Laeyendecker O., et al. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: Hypervariable region 1 as a decoy. J Virol 73 (1999) 2938-2946
140. Booth J.C.L., Kumar U., Webster D., Monjardino J., and Thomas H.C. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 26 (1998) 223-227
141. Virelizier J.L., Allison A.C., and Schild G.C. Antibody responses to antigenic determinants of influenza virus hemagglutinin. II. Original antigenic sin: a bone marrow-derived lymphocyte memory phenomenon modulated by thymus-derived lymphocytes. J Exp Med 140 (1974) 1571-1578
142. Thomssen R., Bonk S., Propfe C., Heermann K.-H., Kochel H.G., and Uy A. Association of hepatitis C virus in human sera with β-lipoprotein. Med Microbiol Immunol 181 (1992) 293-300
143. Prince A.M., Pascual D., McCarthy M., Parker T., and Levine D. Apparent association of HCV RNA with very low density lipoproteins (VLDL). 4th Int. Symp. (1993), HCV 76
144. Prince A.M. Immunity in hepatitis C virus infection. Vox Sang 67 (1994) 227-228
145. Hijikata M., Shimizu Y.K., Kato H., et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 67 (1993) 1953-1958
146. Pileri P., Uematsu Y., Campagnoli S., et al. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
147. Yi M., Kaneko S., Yu D.Y., and Murakami S. Hepatitis C virus envelope proteins bind lactoferrin. J Virol 71 (1997) 5997-6002
148. Monazahian M., Bohme I., Bonk S., et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 57 (1999) 223-229
149. Haywood A.M. Virus receptors: binding, adhesion strengthening and changes in viral structure. J Virol 68 (1994) 1-5